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Tuberculosis (TB) remains a signiicant global health problem. An estimated 10.4 million people developed TB 
and 1.4 million died in 2015 as a result of infection with Mycobacterium tuberculosis, the causative agent of TB1. 
he TB problem is exacerbated by the emergence of multi-drug resistant (MDR) M. tuberculosis, of which there 
were an estimated 440,000 cases in 20082, 3. here have been few major breakthroughs in TB treatment in the last 
50 years4 and as a result there is an urgent need for novel drugs and treatment regimens to combat the spread of 
the disease.
Mycolic acids are vital, major components of the mycobacterial cell wall and their biosynthesis is a key vali-
dated target for many frontline anti-tubercular drugs such as Isoniazid (INH), ethionamide and Isoxyl5, 6. Mycolic 
acids have also recently been the focus of the development of new anti-tuberculosis drugs such as pyridomycin7. 
Mycolic acids are long chain α-alkyl β-hydroxyl fatty acids existing in two main forms in the mycobacterial 
cell; either as unanchored trehalose or glycerol esters, or as anchored mycolic acids, which are linked to the 
arabinogalactan component of the cell wall, contributing to the unique overall cell wall architecture of the myco-
bacteria8. In M. tuberculosis, mycolic acids are biosynthesised through the action of two fatty acid synthases, a 
eukaryotic-like type I and a prokaryotic-like type II enzyme termed FAS I and FAS II respectively. FAS I performs 
the de novo biosynthesis of C16 and C24–26 acyl-CoAs
9. hese medium-length acyl-CoAs then serve as primers for 
the FAS II system, being iteratively condensed through the action of the β-ketoacid-AcpM synthase III (FabH) 
with the malonyl-Acyl carrier protein (AcpM)10, 11. he second stage of elongation requires the action of the 
NADPH-dependent-β-ketoacyl-ACP reductase, MabA, resulting in the formation of β-hydroxyacyl-AcpM. he 
β-hydroxyacyl-AcpM is subsequently dehydrated by the HadABC dehydratases12 and then subsequently reduced 
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by the 2-trans-enoyl-AcpM reductase, InhA13. he successive steps of condensation resulting in the long chain 
meromycolyl-AcpMs (up toC56), which are the direct precursors of mature mycolic acid, are performed by the 
β-ketoacyl-AcpM synthases (KasA and KasB)14, 15.
A key enzymatic step in this pathway is the 2-trans-enoyl-AcpM reductase, InhA, which belongs to a family of 
short-chain reductases13, 16 (Pfam Family PF1356117) and is essential for growth and survival in mycobacteria18.
Recently it has been shown that InhA is controlled post-translationally by phosphorylation19–21, suggesting 
that there is a ine level control over mycolic acid biosynthesis and maturation in mycobacteria. Genetic inactiva-
tion of InhA results in the accumulation of the FAS I end product Hexacosanoic acid (C26) and is similar to that 
observed in INH treated cells18. INH is a pro-drug and in vivo there is a requirement for INH to be activated by 
the catalase peroxidase, KatG, resulting in the formation of a isonicotinoyl radical that reacts with NAD forming 
the InhA inhibitory INH-NAD adduct22. Interestingly much of the clinical resistance observed is due to reces-
sive mutations in several genes (katG, ndh, msh, nat) whereas dominant mutations occur in inhA23. InhA is the 
primary target of INH, ethionamide and triclosan24, 25, given the demonstration that the transfer of the inhA 
S94A mutant allele in M. tuberculosis is suicient to confer resistance to both INH and ethionamide2. Moreover, 
over-expression of inhA also confers resistance to INH in mycobacteria1, 26.
InhA plays and essential role in the biosynthesis of mycolic acids in M. tuberculosis and remains one of our 
primary and validated anti-TB drug targets. Given the rise of MDR-TB in the clinic it is important that a full 
understanding of the catalytic mechanism of this enzyme is obtained. Speciically, the role played by all potential 
molecular contacts with substrate, cofactors and inhibitors and how these residues contribute to overall enzyme 
functionality will give us a better understanding of how to design more potent inhibitors of their activity. Here we 
examine previously unstudied catalytic pocket residues through mutations in terms of their kinetics relating to 
NADH and DD-CoA substrate binding and turnover. We demonstrate that mutation of NADH-binding pocket 
residues can have profound efects on DD-CoA binding and suggest that there are long range molecular interac-
tions in the InhA protein.

Structural studies of InhA performed by Rozwarski et al.3, 27, suggest that hydrogen-bonding interactions within 
the NADH binding pocket of InhA are key to INH inhibitory activity. To investigate this, single point mutations 
of InhA were made that potentially disrupt key molecular interactions. he S94A mutation is known to confer 
INH resistance in the clinic and in experimental studies, with the direct role of this residue believed to be via coor-
dination of a water molecule, within a wider hydrogen-bonding network4, 27. he work of Rozwarski et al.5, 6, 27, 
suggests that M155 interacts indirectly with the nicotinamide ring of NADH or the pyridine ring of the INH-NAD 
adduct via a coordinated water molecule. he hydrophobic residues P193 and W222 are part of a series of hydro-
phobic residues that surround the pyridine ring of the isonicotinic acyl group7, 27 (Fig. S1).
To establish the biochemical role of each of these residues, each site was mutagenized (Oligonucleotides are 
detailed in Table 1) to an alanine residue and the resulting mutant enzymes were assayed for biochemical function 
with the natural substrates NADH and DD-CoA and the ability to turnover NADH was tested in the presence of 
the drug adduct INH-NAD and compared to the WT InhA enzyme. All puriied mutant proteins were subjected 
to Circular Dichroism (CD), to evidence correct folding of the mutant proteins. he CD spectra of WT and all 
mutant proteins exhibited spectra that could be superimposed on each other, indicating that changes to enzyme 
activity was not due to misfolding or major overall structural changes (data not shown).
ǦǤ An overall kinetic analysis of WT InhA, 
InhA S94A, InhA M155A, InhA P193A and InhA W222A proteins is summarised in Tables 2 and 3 and Fig. 1. 
he WT and S94A InhA alleles exhibited similar values to those previously obtained in the literature and served 
as useful benchmark values with which to understand the role the additional residues that were studied here.
As previously shown8, 16, the S94A mutation has similar activity compared to WT but a reduced NADH ainity 
(Km), albeit with an increased Vmax (Tables 2 and 3). Here we show that the ainity of InhA S94A for DD-CoA is 
also decreased, with a Km of 106 µM compared to 75 µM for WT InhA, again however there is also an increase in 
Vmax (Tables 2 and 3). he InhA S94A mutant kcat NADH and kcat DD-CoA was found to have increased 1746 min
−1 
and 789 min−1 respectively compared to 1022 min−1 and 694 min−1 for WT InhA. he kcat/Km ratio for NADH 
indicates that the eiciency of the S94A mutants is 82% of the WT (Table 2: kcat/Km of 8.5 µM
−1 min−1 compared 
Allele Oligonucleotide sequence
InhA Forward (F) - 5′-cgacggggtggtgcatgcgattgggttca-3′
S94A Reverse (R) - 5′-tgaacccaatcgcatgcaccaccccgtcg-3′
InhA F- 5′-cccgagccgggcggcgccggcctacaac-3′
M155A R- 5′-gttgtaggccggcgccgcccggctcggg-3′
InhA F- 5′-gttgccgcaggcgctatccggacgc-3′
P193A R- 5′-gcgtccggatagcgcctgcggcaac-3′
InhA F- 5′-gctcgaggagggcgcggatcagcgcgct-3′
W222A R- 5′-agcgcgctgatccgcgccctcctcgagc-3′
Table 1. Site-directed mutagenesis oligonucleotides used to generate mutant InhA proteins. Underlined 
sequence indicates the altered codon within the oligonucleotide.
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to 10.4 µM−1 min−1). he kcat/Km ratio for DD-CoA indicates around 80% eiciency of the S94A mutant com-
pared to the WT InhA.
he activity of an InhA M155A mutant was assessed to gain insight in to its efect on NADH and DD-CoA 
turnover. Interestingly the Vmax for NADH was equivalent to that of WT, however the M155A mutants Vmax for 
DD-CoA was around 64% of the WT rate (Fig. 1 and Tables 2 and 3). Overall the M155A mutant had an increased 
ainity (Km) for NADH (Table 2: 65 µM compared to 98 µM for WT). Moreover, modifying the M155 residue 
signiicantly increases the ainity of the mutant for DD-CoA (Table 3: 26 µM compared to 75 µM for WT). kcat of 
the InhA M155A mutant for NADH was similar to that of WT InhA (Table 2) however the kcat for DD-CoA was 
around 64% of the WT, suggesting that there may be long range structural interactions within the protein that are 
negatively afected by mutation of the M155 residue.
Allele Activity* (%)
Km[NADH] 
(µM)
Vmax[NADH] (µM 
min−1) kcat (min−1)
kcat/Km[NADH] 
(µM−1 min−1)
WT 100 ± 4 98 ± 23 24.4 ± 5.4 1022 ± 224 10.4 ± 0.3
S94A 93 ± 6 211 ± 36 41.7 ± 6.9 1746 ± 291 8.5 ± 0.2
M155A 104 ± 6 65 ± 14 25.6 ± 4.6 1074 ± 193 16.6 ± 0.3
P193A 1 ± 2 5 ± 3 0.14 ± 0.01 5.8 ± 0.5 1.2 ± 0.6
W222A 58 ± 3 83 ± 7 14.7 ± 1.1 616 ± 45 7.5 ± 0.1
Table 2. NADH dependence (50 µM DD-CoA, 25–150 µM NADH varied). *he Activity column in this table 
is included to show a direct comparison of the initial turnover rates for each allele in the presence of ixed 50 µM 
DD-CoA and 100 µM NADH concentrations. he v0 of the wild-type turnover, v0 (WT), is deined as 100% 
activity, and is used to reference the other alleles. he inal values are listed as percentage ratios of the v0 of each 
allele with respect to v0 (WT) generating the values listed.
Allele
Km[DD-CoA] 
(µM)
Vmax[DD-CoA] 
(µM min−1) kcat (min−1)
kcat/Km[DD-CoA] 
(µM−1 min−1)
WT 75 ± 10 16.6 ± 0.8 694 ± 33 9.3 ± 0.7
S94A 106 ± 13 18.8 ± 1.8 789 ± 74 7.4 ± 1.2
M155A 26 ± 2 10.6 ± 0.5 446 ± 19 17.0 ± 1.5
P193A 53 ± 7 0.6 ± 0.1 25 ± 3 0.5 ± 0.1
W222A 145 ± 51 25.2 ± 8.6 1055 ± 359 7.3 ± 3.6
Table 3. DD-CoA dependence (100 µM NADH, 25–150 µM DD-CoA varied).
Figure 1. Enoyl reductase (ENR) activity of InhA and mutant derivatives. he enzymatic activity of the InhA 
variants and single point mutants were puriied from recombinant E. coli, dialysed and assayed for ENR activity. 
(A) Enzymatic activity with increasing DD-CoA concentration (0–150 µM). Initial velocity for the WT and 
mutant enzymes measured at the NADH concentration of 100 µM. he lines are a it to the data described by 
=
−
+ −
v
V
k
DD CoA
DD CoA0
[ ]
[ ]m
max . (B) Enzymatic activity with increasing NADH concentration (0–150 µM). Initial velocity 
for the WT and mutant enzymes measured at the DD-CoA concentration of 50 µM. he lines are a it to the data 
described by =
+
v
V
k
NADH
NADH0
[ ]
[ ]m
max .
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Mutation of P193 inactivates the ability of InhA to turn over either NADH and DD-CoA (Fig. 1A and B; 
Tables 2 and 3), which is consistent with the proposed role of P193 directly interacting with the nicotinamide 
group. he P193A mutant exhibits a much lower Km for both NADH and DD-CoA, with residual activity of 
the mutant around 1% of the WT InhA. his also leads to much reduced catalytic eiciency of the InhA P193A 
mutant with an NADH kcat of 5.8 min−1 compared to 1022 min−1 for WT InhA, which indicates that this muta-
tion is likely to be integral to the pocket geometry and function. he kcat/Km ratio shows that the enzyme ei-
ciency of InhA P193A with NADH is 12% of the WT and enzyme eiciency for DD-CoA is 5% of the WT. his 
suggests that this proline residue plays a key structural role in the distal area of the NADH binding pocket.
Similar to the role of residue P193, the tryptophan residue 222 is proposed to interact with the nicotina-
mide group9, 27. Kinetic analysis of the InhA W222A mutant indicates a reduction in overall enoyl reductase 
activity (Tables 2 and 3; Fig. 1). he W222A mutant showed an increased ainity (Km) for NADH but with a 
reduced Vmax (Table 2), with a concomitant reduction in kcat when compared to WT InhA. he eiciency of the 
W222A mutant, when considering the kcat/Km ratio shows that it is around 70% of the WT enzyme for NADH. 
Conversely the W222A mutation reduces the ainity of InhA for DD-CoA by around two-fold (Table 3), although 
Vmax is increased along with the kcat for DD-CoA. he kcat/Km ratio shows that the enzyme eiciency of an InhA 
W222A is around 80% of WT (Table 3). While it is proposed to have a similar interaction with NADH as P19327, 
W222 may play a role in the allosteric signalling to the DD-CoA binding region of the protein, or through medi-
ating protein-protein interactions.
ǦǤ To test how the mutant derivatives of InhA behave 
when exposed to the inhibitory drug adduct, the rate of NADH turnover (Vmax) was measured when the proteins 
were incubated with 100 µM INH-NAD, prior to activity assays with the exception of InhA S94A, which showed 
no diference in activity from protein incubated in the absence of INH-NAD and was subsequently incubated 
with 300 µM INH-NAD to demonstrate inhibition (Table 4). hese data indicate that inhibition of all mutants 
with INH-NAD is possible with residual activity following incubation with INH-NAD of 17% for WT InhA, 19% 
for InhA M155A, 23% for InhA W222A. Incubation of InhA P193A with INH-NAD showed a similar level of 
activity as the uninhibited protein, which was already shown to be inactive (Table 4).
Discussion
Previous studies of InhA have identiied key residues that contribute to the mechanism of action of both the 
enzyme10, 11, 28, its activation through phosphorylation12, 19 and also contribute to our knowledge of the mech-
anism of action of the frontline anti-TB drug, INH. he results presented here expand our knowledge of key 
residues in the active site by adding information to our understanding that the role NADH turnover may play 
in potential allosteric mediated interactions with DD-CoA and/or the assembly of multimeric states of InhA. 
Solving the structure of InhA allowed the identiication of residues within InhA responsible for binding NADH 
that may play a key role in binding both natural substrate and the inhibitory drug adduct INH-NAD13, 22, 27. he 
residues studied here were predicted to make signiicant molecular contacts with NADH or INH-NAD and are 
indicated in Fig. S1.
InhA mutations in clinical INH resistant strains are generally located in the NADH binding pocket14–16, 29, 
with a key residue being S94. his study of an S94A mutant conirmed previous data12 that this single residue 
change results in an increased turnover of the NADH substrate, via an increase in Vmax coupled with a reduced 
ainity (Km) for NADH and the INH-NAD adduct, however this reduced ainity is not suicient to explain drug 
resistance. he data presented here support this hypothesis, indicating that mutations resulting in altered geome-
try in the NADH binding pocket may have signiicant efects elsewhere in the protein, with the DD-CoA ainity 
of the S94A mutant also being altered despite the distance from this region of the protein. Moreover, the M155 
and P193 mutations afect DD-CoA turnover and ainity in addition to the local efects observed in the NADH 
binding pocket. hese observations it with inter- and intramolecular signalling hypotheses of Rawat et al.13, 16, 29. 
and indicates that further work on interactions with the FASII complex and the molecular dynamics of the pro-
tein would be valuable in fully elucidating the mechanism of mycolic acid biosynthesis.
Work by Rawat et al.17, 29, also suggests that there is a two-step mechanism for InhA binding the INH-NAD 
adduct, where an initial weak binding of the adduct is followed by slow conversion to a tightly inhibited complex. 
Allele Vmax (µM min
−1)
InhA WT 24.4 ± 5.4
InhA WT (100 µM INH-NAD) 4.2 ± 0.3 (17%)
InhA S94A 41.7 ± 6.0
InhA S94A (300 µM INH-NAD) 16.7 ± 1.7 (40%)
InhA M155A 25.6 ± 4.6
InhA M155A (100 µM INH-NAD) 4.9 ± 1.1 (19%)
InhA P193A 0.14 ± 0.01
InhA P193A (100 µM INH-NAD) 0.14 ± 0.01 (N/A)
InhA W222A 14.7 ± 1.1
InhA W222A (100 µM INH-NAD) 3.4 ± 0.2 (23%)
Table 4. Activity and inhibition of InhA and mutant derivatives in the presence of INH-NAD. Concentration of 
adduct is indicated in brackets for inhibited reactions.
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Moreover, these authors suggest that protein-protein interaction, supported by the work of Bloch and others18, 30, 31, 
between multiple FASII pathway enzymes (including InhA) result in the formation of a functional mycolic acid 
biosynthetic complex. It is believed that these interactions may modulate the catalytic activity of InhA when a 
functional tetramer is formed and in a complex with other FASII enzymes gives rise to the appearance of allosteric 
binding characteristics of InhA kinetics19–21, 29, 32.
Intriguingly, an M155A mutation has an apparent decreased Km for NADH and decreased Km for DD-CoA 
suggesting an overall gain of function mutation via M155. hese data show that mutation of a key NADH-binding 
pocket residue can have profound efects of other regions and activities of the enzyme. his is not simply medi-
ated through binding of a substrate (NADH or INH-NAD) in the NADH-binding pocket as the InhA M155A 
mutant is inhibited by the INH-NAD drug adduct in a similar manner to WT InhA. hese data suggest that the 
dynamics of catalytic activity and inhibition are subtler than previously thought and may point towards long 
range interactions within the molecule that are not easily observed through static crystallography approaches.
In summary, mutagenesis of key residues in the NADH-binding pocket of InhA can alter the enzymatic 
properties of both substrate binding pockets in a subtle manner and suggest that long-range intramolecular 
interactions may afect substrate turnover and binding for each of the substrates. Currently it is unclear how 
these mutations may afect assembly of the FASII protein complexes, but further work in these areas will allow 
deeper insight in to the inhibition of a fundamental cellular process for M. tuberculosis and may lead to novel 
therapeutics.

ȂEscherichia coliǤ DH5α (Invitrogen) was used for standard cloning/
transformation and E. coli BL21 (DE3) Star (Novagen) was used for protein expression.
ǦǡƤ-
Ǥ InhA was expressed from the plasmid pETPhos_inhAWT (N-terminal Histidine tagged). Site-Directed 
Mutants (SDMs) were constructed using the QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies) 
according to the manufacturer’s instructions. SDM oligonucleotides are detailed in Table 1. All SDM plasmids 
were conirmed by sequencing. BL21 (DE3) Star freshly transformed with Wild-Type or mutant InhA plasmids 
were grown in LB medium with 100 µg ml−1 carbenicillin (Melford labs) overnight at 37 °C. hese overnight 
cultures were used to inoculate 500 ml of LB and were grown under the same conditions, with shaking until they 
reach an A600 = 0.5. Isopropyl-thio-β-D-galactopyranoside (IPTG) was added to a inal concentration of 1 mM 
and incubation was continued for 3 h at 37 °C. Cells were collected by centrifugation (4000 × g, 10 mins), washed 
and resuspended in Bufer A (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 10% Glycerol, and 20 mM imidazole) 
with Complete EDTA-Free Protease inhibitor cocktail (Roche) and Benzonase (Sigma-Aldrich). Cells were lysed 
using BugBuster (Novagen) according to the manufacturer’s instructions and lysates were clariied by centrifu-
gation (4000 × g, 10 mins). InhA was puriied by Ni2+-ainity chromatography (His-Trap, GE Healthcare) using 
an AKTA chromatography system. InhA was eluted from the column using Bufer B (20 mM Tris-HCl, pH 7.5, 
500 mM NaCl, 10% Glycerol and 1 M imidazole). Fractions containing pure InhA (with the histidine-tag still 
intact, but has no efect on activity18, 28) were pooled, dialysed to remove imidazole and concentrated as required 
and stored in 20% glycerol at −20 °C as required. All data reported are the result of three technical replicates gen-
erated from three independent biological (independent over-expression) replicates.
Ǥ he enoyl reductase activity of InhA was assayed spectrophotomet-
rically following the oxidation of NADH to NAD+ at 340 nm. All measurements (unless stated) were performed 
using a Shimadzu UV-2550 dual-beam absorption spectrometer (Shimadzu Scientiic Instruments). Reactions 
were carried out at 37 °C in 100 mM phosphate bufer, pH7.5 containing 1.47 µM of InhA (Wild-type or mutant 
protein) and varying levels of NADH and the trans−2-Dodecenoyl-Coenzyme A (DD-CoA) substrate. he data 
all activity measurements were single cuvette measurements run in triplicate over a total duration of 300 sec-
onds. he DD-CoA substrate was synthesised from 2-Dodecenoic acid (Obtained from Enamine Ltd) using the 
anhydride method of Quémard et al.13, 22. he INH-NAD adduct was synthesised in the presence of InhA, pro-
ducing inhibited InhA according to the method of Rozwarski et al.22, 23, where 350 µM WT or mutant InhA was 
incubated in 50 mM HEPES bufer (pH 7.5) with 17.5 mM NADH, 35 mM INH and 3.5 mM MnCl2. Inhibition 
assays for all alleles were conducted by removing aliquots from the incubation mixture previously described and 
spectrophotometrically monitoring the turnover of NADH to NAD+ at 340 nm in the presence of DD-CoA in 
the same manner as for the activity assays. All control reactions were collected simultaneously consisting of a 
ixed 100 µM concentration of NADH and the appropriate amount of DD-CoA but in the absence of enzyme. 
he kinetic parameters for all assays were determined at a ixed, saturating concentration of either NADH or 
DD-CoA (100 µM and 50 µM respectively), whilst varying the substrate or cofactor accordingly. hus allowing the 
kinetics of inhibited WT InhA and mutant InhA to be determined under appropriate conditions. Values for Km 
and Vmax for each allele were calculated from a plot of a series of v0 values determined experimentally by varying 
one substrate concentration whilst the holding other at a ixed value. Values for Km and Vmax initially as a function 
of [NADH] and then [DD-CoA] are obtained directly by non-linear regression itting of the Michaelis-Menten 
equation,
=
+
v
V
k
substrate
substrate
[ ]
[ ]
m
max
0
(where [substrate] represents [DD-CoA] or [NADH]) to the data. The equation was incorporated as a 
user-deined itting function into the curve itting analysis suite within the Igor Pro 6.37 [Wavemetrics] sotware 
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which was used in all data/statistical analysis procedures. he itting procedure utilises the Levenberg-Marquardt 
algorithm or Nonlinear Least-Squares method which returns estimates for Km and Vmax along with the standard 
error (±2σ) taken as the uncertainty.
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